MARKET

ARDX

ARDX

Ardelyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.93
+0.28
+4.96%
Closed 16:00 11/23 EST
OPEN
5.77
PREV CLOSE
5.65
HIGH
6.03
LOW
5.62
VOLUME
645.25K
TURNOVER
--
52 WEEK HIGH
8.82
52 WEEK LOW
4.220
MARKET CAP
535.17M
P/E (TTM)
-5.8269
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that a webcast of Mike Raab, president and chief executive officer of Ardelyx, and Susan Rodriguez, chief commercial officer, participating in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference will be available today at 10 a.m. ET.
PR Newswire · 22h ago
Ardelyx to Webcast Virtual Analyst Day
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that it will hold a virtual Analyst Day on Thursday, November 12, 2020, from 9:30 a.m. to 12:00 p.m. ET. This year's event will focus on the company's launch and commercialization plans in anticipation of the potential approval of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Additionally, the company will review its pipeline therapeutic for hyperkalemia.
PR Newswire · 11/06 13:00
Ardelyx, Inc. (NASDAQ:ARDX) Analysts Just Slashed Next Year's Revenue Estimates By 32%
The analysts covering Ardelyx, Inc. (NASDAQ:ARDX) delivered a dose of negativity to shareholders today, by making a...
Simply Wall St. · 11/06 10:28
Ardelyx EPS beats by $0.08, beats on revenue
Ardelyx (ARDX): Q3 GAAP EPS of -$0.20 beats by $0.08.Revenue of $2.71M (-10.0% Y/Y) beats by $1.81M.Press Release
Seekingalpha · 11/05 13:19
Ardelyx Q3 EPS $(0.20) Up From $(0.37) YoY, Sales $2.71M Down From $3.01M YoY
Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.20) per share. This is a 45.95 percent increase over losses of $(0.37) per share from the same period last year. The company reported $2.71 million in sales this
Benzinga · 11/05 13:08
Will Ardelyx (ARDX) Report Negative Q3 Earnings? What You Should Know
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 10/28 17:33
Ardelyx, Kyowa Kirin Highlight New Clinical Data Presented Within 5 Posters For Kidney Week 2020
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company developing targeted, first-in-class medicines to improve the lives of patients with kidney and cardiovascular diseases, and Kyowa Kirin Co., Ltd. (Kyowa Kirin,
Benzinga · 10/22 14:01
Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company developing targeted, first-in-class medicines to improve the lives of patients with kidney and cardiovascular diseases, today announced the launch of its 'Can We Do Better?' Campaign at Kidney Week 2020, this year's virtual Annual Meeting of the American Society of Nephrology (ASN) that is now underway. With a new and deeper mechanistic understanding of phosphate absorption, Ardelyx is developing a new approach to advance patient care.
PR Newswire · 10/22 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARDX. Analyze the recent business situations of Ardelyx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARDX stock price target is 13.00 with a high estimate of 15.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 166
Institutional Holdings: 85.45M
% Owned: 94.68%
Shares Outstanding: 90.25M
TypeInstitutionsShares
Increased
32
2.20M
New
41
584.45K
Decreased
38
2.80M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Michael Raab
Chief Financial Officer/Chief Accounting Officer
Justin Renz
Chief Administrative Officer
Elizabeth Grammer
Other
Susan Rodriguez
Other
David Rosenbaum
Independent Director
Robert Bazemore
Independent Director
William Bertrand
Independent Director
Geoffrey Block
Independent Director
Onaiza Cadoret-Manier
Independent Director
Jan Lundberg
Independent Director
Gordon Ringold
Independent Director
Richard Rodgers
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ARDX
Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Ardelyx Inc stock information, including NASDAQ:ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.